about
Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutationAmyloidosis in Retinal Neurodegenerative DiseasesMechanisms of Aβ Clearance and Degradation by Glial CellsCandidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's diseaseMisframed ubiquitin and impaired protein quality control: an early event in Alzheimer's diseaseThe low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer's diseaseThe involvement of microRNAs in neurodegenerative diseasesApolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer diseaseMolecular Basis of Substrate Recognition and Degradation by Human Presequence ProteaseRegulation of distinct pools of amyloid β-protein by multiple cellular proteasesNeuroinflammation in Alzheimer's diseaseAC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model.Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1Cross-talk of membrane lipids and Alzheimer-related proteins.Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's DiseaseNeuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.LCAT deficiency does not impair amyloid metabolism in APP/PS1 miceEnhanced Aβ(1-40) production in endothelial cells stimulated with fibrillar Aβ(1-42)A lipoprotein receptor cluster IV mutant preferentially binds amyloid-β and regulates its clearance from the mouse brainAmyloid-β efflux from the central nervous system into the plasma.Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's diseaseTime dynamics of protein complexes in the AD11 transgenic mouse model for Alzheimer's disease like pathology.Deciphering Alzheimer disease.Overexpression of the Insulin-Like Growth Factor II Receptor Increases β-Amyloid Production and Affects Cell Viability.TANGO-Inspired Design of Anti-Amyloid Cyclic Peptides.The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer's disease.The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.The Role of Neutrophil Proteins on the Amyloid Beta-RAGE Axis.Mathematical model on Alzheimer's diseaseLow-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.Aggregated Alpha-Synuclein Transfer Efficiently between Cultured Human Neuron-Like Cells and Localize to LysosomesAcute and Chronic Sustained Hypoxia Do Not Substantially Regulate Amyloid-β Peptide Generation In VivoThe synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system.Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysinApolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's diseaseEndothelin-converting enzymes degrade intracellular β-amyloid produced within the endosomal/lysosomal pathway and autophagosomes.Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes.The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjectsAge and its association with low insulin and high amyloid-β peptides in blood
P2860
Q24337087-F1A0369E-2313-4C49-9130-5F4BFF18E417Q26739839-30995B34-00FB-4826-AA8A-BE0839F0671AQ26741609-C93C1BE5-C855-4040-BD52-9FA8E890C515Q26753192-0CCE04AF-6380-49A6-82FC-2C5814D8C0AAQ26782999-4CD8D631-0F4D-49CC-BFC8-ED2E83D5A7BBQ26827353-3346BEE7-981F-441F-B57C-1506E30AC7ECQ26858788-FA158D5E-0449-4DE4-9756-09220E022ADBQ26858870-A0246F0C-9568-49E5-B3C3-2BB2931E3AD4Q27684349-1C687917-267B-4CF6-95D4-E8E421DF1A32Q27694752-52AD7D96-7EFB-44A4-AD06-5B5D7BAFBCF4Q28259238-2C212CF7-E7EF-482F-A890-8463EDCF1150Q30430690-AF9E0CB0-D78E-477B-846E-5E111193A807Q33362745-05611AFF-166E-4562-8924-E289B4CFCCACQ33592538-BF4B8D0B-E7CA-4A55-AC90-16DE7EDDC13DQ33628048-18BDF1D0-7745-4C3B-9847-660E54F6C4ACQ33755982-D8CCF770-58BA-40C8-9101-BEFC3B3BC5E9Q33908201-F3D202A2-8FE0-4C32-A06D-2B3E0F143786Q33945108-B6CE9112-A713-4D77-9A26-BE2A73956B06Q34625636-8B8353A9-57BD-444F-975E-D8DC741F37A1Q34666433-62351C57-67A4-45B0-96A1-4F5AF1B9D4C5Q35166482-B0E41DAF-80A0-4507-B609-C75971F0094FQ35559895-C6F9FE53-C49F-40A9-AC32-FE9B0B131D70Q35618276-B24BAFA6-32EC-45F2-9612-F6B21110747BQ35658189-931E7FC4-D2FD-4176-B9B3-BE51873494A0Q35764183-D8AACDDC-CAC9-485D-A9DE-DE9AECD72F29Q36062167-2310F674-A950-4B1A-8259-15122BF9DBA0Q36073680-2F772581-3BE6-4872-8593-67EAC672CC92Q36119393-CBFEF232-8CEF-49D8-9A2E-D6BF8C76ABA2Q36146033-444C0E26-3610-4988-A392-ECA16EBCDBB2Q36198218-BB2C8E8A-F1E8-4E42-9DD7-55AC93C98A76Q36205039-60D084E5-3575-4452-93E1-EAEADE494B7FQ36234756-82949D06-9AE2-4A7C-ACD3-DB6432CCF846Q36252648-F77A559D-5717-44E5-A52D-8595B8F557E6Q36295481-B9CA22D3-DA4C-49A8-A3E8-BC222CBE6326Q36319298-48990FD8-1EDE-4FA9-8723-91D4029B323EQ36424857-4406E455-1723-45EA-8E22-46086E8B0BFBQ36635917-20FD905E-CF90-48DF-982E-30B920DF4561Q36691483-3FB5FB58-0573-462D-B161-9AA9DAFCCEDCQ36806654-186C75ED-77C4-4E09-880F-9330AA88CDA3Q36809956-CB4DF9F0-4B71-4A70-B9B3-C1A755FE3740
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Proteolytic degradation of amyloid β-protein.
@en
type
label
Proteolytic degradation of amyloid β-protein.
@en
prefLabel
Proteolytic degradation of amyloid β-protein.
@en
P2860
P1476
Proteolytic degradation of amyloid β-protein.
@en
P2093
Malcolm A Leissring
Takaomi Saido
P2860
P304
P356
10.1101/CSHPERSPECT.A006379
P577
2012-06-01T00:00:00Z